Fig. 4From: Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphomaHE staining and IHC of six patients available. The scan of case 2 in the left two images showed a relatively hypermetabolic lesion in mediastinal, hilar lymph nodes, and intestines after using pembrolizumab for 1Â cycle. The two images on the right showed that the lesions were metabolically less active 2Â cycles laterBack to article page